Insider Buying: Amyris Inc (AMRS) COO Acquires 11,834 Shares of Stock

Share on StockTwits

Amyris Inc (NASDAQ:AMRS) COO Eduardo Alvarez purchased 11,834 shares of the firm’s stock in a transaction on Thursday, December 13th. The stock was acquired at an average price of $4.23 per share, with a total value of $50,057.82. Following the completion of the purchase, the chief operating officer now owns 333,876 shares of the company’s stock, valued at approximately $1,412,295.48. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of AMRS stock traded down $0.12 during mid-day trading on Friday, reaching $4.09. The stock had a trading volume of 1,075,233 shares, compared to its average volume of 1,499,206. Amyris Inc has a 1-year low of $3.19 and a 1-year high of $9.28.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.96). The firm had revenue of $14.90 million during the quarter, compared to analyst estimates of $46.72 million. The business’s revenue for the quarter was down 38.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.81) earnings per share. Research analysts anticipate that Amyris Inc will post -1.34 EPS for the current year.

A number of equities research analysts have commented on AMRS shares. HC Wainwright set a $15.00 price target on Amyris and gave the company a “buy” rating in a research note on Thursday, October 4th. BidaskClub lowered Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, November 13th. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Finally, B. Riley set a $10.00 price objective on Amyris and gave the company a “buy” rating in a report on Monday, September 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Amyris presently has an average rating of “Buy” and a consensus price target of $8.83.

Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. acquired a new stake in Amyris during the second quarter worth about $292,000. Gilder Gagnon Howe & Co. LLC acquired a new stake in Amyris during the third quarter worth about $7,828,000. BlackRock Inc. grew its holdings in Amyris by 3,109.9% during the second quarter. BlackRock Inc. now owns 1,714,555 shares of the biotechnology company’s stock worth $10,955,000 after acquiring an additional 1,661,141 shares during the period. Northpointe Capital LLC acquired a new stake in Amyris during the third quarter worth about $3,646,000. Finally, B. Riley Financial Inc. grew its holdings in Amyris by 80.0% during the second quarter. B. Riley Financial Inc. now owns 79,219 shares of the biotechnology company’s stock worth $508,000 after acquiring an additional 35,219 shares during the period. 32.21% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first published by BBNS and is the property of of BBNS. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://baseballnewssource.com/2018/12/16/insider-buying-amyris-inc-amrs-coo-acquires-11834-shares-of-stock/3085055.html.

About Amyris

Amyris, Inc, an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.

See Also: How do investors use RSI to grade stocks?

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.